MYCOBACTERIUM TUBERCULOSIS BIOLOGICAL PROPERTIES AND CHARACTERISTICS OF THE INFLAMMATORY REACTION IN PATIENTS WITH INFILTRATIVE PULMONARY TUBERCULOSIS

Cover Page

Cite item

Abstract

Host-pathogen relations were analyzed on basis of the results of examinations of 42 patients with newly diagnosed, previously untreated infiltrative pulmonary tuberculosis (IPT) with regard for the biological characteristics of Mycobacterium tuberculosis (MBT) and the biomarkers of the inflammatory reaction — the acute phase proteins (APPs). The genotypes of MBT (Beijing and the others) and the efficacy of threeonth antituberculosis therapy were used as the grouping factors. Genotype Beijing MBT patients were significantly often characterised by multiple drug resistant, had widespread pulmonary damage and association of MBT cytoxicity with the effect of therapy. The patients with the best postreatment effect had initial (pretreatment) APPs levels in the range of the referent ones. These conclusions were confirmed by analysis of the correlation pleads of the characteristics of the “host-pathogen” system and their discriminant analysis with regard for MBT genotypes and results of antituberculosis three-month therapy. It was shown that the constellation of four host’s APP characteristics (haptoglobin, ceruloplasmin, elastase and adenoaminase activities) has above 90% prognostic efficacy of treatment in spite of MBT genotype. It is suggested that in IPT patients the first component of the “host-pathogen” system reflecting the reaction of the patient’s organism to the MBT induced inflammatory process is more prognostically important.

About the authors

O. T. Titarenko

St. Petersburg Research Institute of Phthisiopulmonology, St. Petersburg

Author for correspondence.
Email: olga-titarenko39@yandex.ru
PhD (Medicine), Head of the Laboratory of the Pathogenetic Researches Russian Federation

M. E. Dyakova

St. Petersburg Research Institute of Phthisiopulmonology, St. Petersburg

Email: fake@neicon.ru

PhD (Biology), Senior Researcher, Laboratory of the Pathogenetic Researches, St. Petersburg Research Institute of Phthisiopulmonology

Russian Federation

O. A. Manicheva

St. Petersburg Research Institute of Phthisiopulmonology, St. Petersburg

Email: fake@neicon.ru

PhD, MD (Biology), Leading Researcher, Laboratory of the Etiologic Diagnostics, St. Petersburg Research Institute
of Phthisiopulmonology

Russian Federation

D. S. Esmedlyaeva

St. Petersburg Research Institute of Phthisiopulmonology, St. Petersburg

Email: fake@neicon.ru

PhD (Biology), Senior Researcher, Laboratory of the Pathogenetic Researches, St. Petersburg Research Institute of Phthisiopulmonology

Russian Federation

M. Z. Dogonadze

St. Petersburg Research Institute of Phthisiopulmonology, St. Petersburg

Email: fake@neicon.ru

PhD (Biology), Senior Researcher, Laboratory of the Etiologic Diagnostics, St. Petersburg Research Institute
of Phthisiopulmonology

Russian Federation

N. P. Alexeyeva

St. Petersburg Research Institute of Phthisiopulmonology, St. Petersburg

Email: fake@neicon.ru

PhD (Physics and Mathematics), Programmer, Department of the Scientific Technical Information, St. Petersburg Research Institute of Phthisiopulmonology

Russian Federation

T. L. Perova

St. Petersburg Research Institute of Phthisiopulmonology, St. Petersburg

Email: fake@neicon.ru
Researcher, Laboratory of the Pathogenitic Researches, St. Petersburg Research Institute of Phthisiopulmonology Russian Federation

N. N. Melnikova

St. Petersburg Research Institute of Phthisiopulmonology, St. Petersburg

Email: fake@neicon.ru

PhD (Medicine), Senior Researcher, Laboratory of the Etiologic Diagnostics, St. Petersburg Research Institute
of Phthisiopulmonology

Russian Federation

References

  1. Барнаулов А.О. Клиническое значение и эффективность лечения туберкулеза легких 1. в зависимости от степени цитотоксичности возбудителя: автореф. дис. … канд. мед. наук. СПб., 2010. 22 c. [Barnaulov A.O. Klinicheskoe znachenie i effektivnost` lecheniya tuberkuleza legkikh v zavisimosti ot stepeni tsitotoksichnosti vozbuditelya: avtoref. dis. … kand. med. nauk [Clinical value and treatment efficacy of pulmonary tuberculosis in dependence on degree of the pathogen cytotoxicity. Autoref. Med. Sci. diss]. SPb., 2010, 22 p.].
  2. Глотова Е.В., Абдуллаев Р.Ю., Чеботарева Т.В., Облогина Л.И. Оценка синдрома системного воспалительного ответа у больных с впервые выявленным туберкулезом легких // Туберкулез и болезни легких. 2011. № 11. С. 8–11. [Glotova E.V., Abdullaev R.Yu., Chebotareva T.V., Oblogina L.I. Otsenka sindroma sistemnogo vospalitel`nogo otveta u bol`nykh s vpervye vyyavlennym tuberkulezom legkikh [Estimation of the systemic inflammatory response syndrome in patients with newly diagnosed pulmonary tuberculosis]. Tuberkulez i bolezni legkikh = Tuberculosis and Lung Diseases, 2012, no. 11, pp. 8–11.].
  3. Елькин А.В., Титаренко О.Т., Эсмедляева Д.С., Дьякова М.Е., Алексеева Н.П., Перова Т.Л. Оценка риска послеоперационных инфекционных осложнений у больных фиброзно-кавернозным туберкулезом легких // Туберкулез и болезни легких. 2009. № 5. С. 31–33. [El`kin A.V., Titarenko O.T., Esmedlyaeva D.S., D`yakova M.E., Alekseeva N.P., Perova T.L. Otsenka riska posleoperatsionnykh infektsionnykh oslozhneniy u bol`nykh fibrozno-kavernoznym tuberkulezom legkikh [Assessment of postsurgery infections complications rick in patients with fibro-covernous pulmonary tuberculosis]. Tuberkulez i bolezni legkikh = Tuberculosis and Lung Diseases, 2009, no. 5, pp. 31–33.].
  4. Каминская Г.О., Абдуллаев Р.Ю., Мартынова Е.В., Серебряная Б.А., Комиссарова О.Г. Синдром системного воспалительного ответа при туберкулезе легких // Туберкулез и болезни легких. 2009. № 11. С. 40–48. [Kaminskaya G.O., Abdullaev R.Yu., Martynova E.V., Serebryanaya B.A., Komissarova O.G. Sindrom sistemnogo vospalitel`nogo otveta pri tuberkuleze legkikh [Syndrome of systemic inflammatory response in pulmonary tuberculosis]. Tuberkulez i bolezni legkikh = Tuberculosis and Lung Diseases, 2009, no. 11, pp. 40–48.].
  5. Маничева О.А., Нарвская О.В., Мокроусов И.В., Вязовая А.А., Журавлев В.Ю., Барнаулов А.О., Догонадзе М.З., Оттен Т.Ф., Вишневский Б.И. Лекарственная устойчивость, жизнеспособность и вирулентность in vitro штаммов Mycobacterium tuberculosis различных генотипов // Инфекция и иммунитет. 2011. Т. 1, № 4. С. 341–348. [Manicheva O.A., Narvskaya O.V., Mоkrousov I.V., Vyazovaya A.A., Zhuravlev V.Yu., Barnaulov A.O., Dogonadze M.Z., Otten T.F., Vishnevskiy B.I. Lekarstvennaya ustoychivost`, zhiznesposobnost` i virulentnost` in vitro shtammov Mycobacterium tuberculosis razlichnykh genotipov [Drug resistency, viability and virulence in vitro of the Mycobacterium tuberculosis strains of different genotypes]. Infektsiya i immunitet = Infection and Immunity, 2012, vol. 1, no. 4, pp. 341–348.].
  6. Павлов В.А., Медвинский И.Д., Чучаев Ю.П., Сабодаш Е.В. Защитно-адаптивные механизмы при туберкулезной инфекции // Фтизиатрия и пульмонология. 2011. № 1. С. 42–54. [Pavlov V.A., Medvinskiy I.D., Chuchaev Yu.P., Sabodash E.V. Zashchitno-adaptivnye mekhanizmy pri tuberkuleznoy infektsii [Adaptive-protective mechanisms in case of tuberculosis infection]. Ftiziatriya i pul`monologiya = Phtisiology and Pulmonology, 2011, no. 1, pp. 42–54.].
  7. Титаренко О.Т., Дьякова М.Е., Павлова М.В., Эсмедляева Д.С., Алексеева Н.П., Перова Т.Л. Клинико-лабораторные сопоставления в оценке прогноза лечения больных инфильтративным туберкулезом легких // Клиническая лабораторная диагностика. 2012. № 5. С. 31–34. [Titarenko O.T., D`yakova M.E., Pavlova M.V., Esmedlyaeva D.S., Alekseeva N.P., Perova T.L. Kliniko-laboratornye sopostavleniya v otsenke prognoza lecheniya bol`nykh infil`trativnym tuberkulezom legkikh [The clinical laboratory comparison in the assessment of treatment prognosis in patients with infiltrative tuberculosis of lungs]. Klinicheskaya laboratornaya diagnostika = Clinical Laboratory Diagnostics, 2012, no. 5, pp. 31–34.].
  8. Титаренко О.Т., Дьякова М.Е., Перова Т.Л., Ряснянская Т.Б. Активность аденозиндезаминазы и ее изоферментов у больных с различными формами туберкулеза // Туберкулез и болезни легких. 2002. № 3. С. 43–45. [Titarenko O.T., D`yakova M.E., Perova T.L., Ryasnyanskaya T.B. Aktivnost` adenozindezaminazy i ee izofermentov u bol`nykh s razlichnymi formami tuberkuleza [Activity of adenosine deaminase and its isoenzymes in patients with different forms of tuberculosis]. Tuberkulez i bolezni legkikh = Tuberculosis and Lung Diseases, 2002, no. 3, pp. 43–45.].
  9. Almeida M.L., Barbieri M.A., Gurgel R.Q., Abdurrahman J.T. α1-acid glycoprotein and α1-antitrypsin as early markers of treatment response in patients receiving the intensive phase of tuberculosis therapy. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2009, vol. 103, pp. 575–580.
  10. Bogolyubova G.M., Sankovsky A.A., Sherbak J.G. A method of inactivating alpha 2 macroglobulin in blood plasma. Lab. Delo, 1988, no. 11, pp. 13–15.
  11. Breen R.A.M., Leonard O., Perrin F.M.R., Smith C.J., Bhagani S., Cropley L., Lipman M.C.I. How good are systemic symptoms and blood inflammatory markers at defecting individuals with tuberculosis? Inf. J. Tuberc. Lung Dis., 2008, vol. 12, no. 1, pp. 44–49.
  12. Castro-Garza J., Barrios-Garc a H., Cruz-Vega D., Said-Fernandez S., Carranza-Rosales P., Molina-Torres C., Vera-Cabrera L. Use of a colorimetric assay to measure differences in cytotoxicity of Mycobacterium tuberculosis strains. J. Medical Microbiol., 2007, vol. 56, pp. 733–737.
  13. Cooper A.M., Mayer-Barber K.D., Sher A. Role of innate cytokines in mycobacterial infection. Mucosal Immunology, 2011, vol. 4, no. 3, pp. 252–260.
  14. Caws M., Thwaites G., Dunstan S., Hawn T.R, Lan N.T.N., Thuong N.T.T., Stepniewska K., Huyen M.N.T., Bang N.D., Loc T.H., Gagneux S., Soolingen D., Kremer K., Sande M., Small P., Anh P.T., Chinh N.T., Quy H.T., Duyen N.T.H., Tho D.Q., Hieu N.T., Torok E., Hien T.T., Dung N.H., Nhu N.T.Q., Duy P.M., Chau N.V., Farrar J. The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog., 2008, vol. 4, pp. 1–9.
  15. Dietrich J., Doherty M. Interaction of Mycobacterium tuberculosis with the host: consequence for vaccine development. APMIS, 2009, vol. 117, iss. 5–6, pp. 440–457.
  16. Drobniewski F., Balabanova Y., Nikolayevsky V., Ruddy M., Kuznetzov S., Zakharova S., Melentyev A., Fedorin I. Drug-resistant tuberculosis, clinical virulence, and the dominance of the Beijing strain family in Russia. JAMA, 2005, vol. 293, no. 22, pp. 2726–2731.
  17. Forrellad M.A., Klepp L.I., Gioffr A., Sabio y Garc a J., Morbidoni H.R., de la Paz Santangelo M., Cataldi A.A., Bigi F. Virulence factors of the Mycobacterium tuberculosis complex. Virulence, 2013, vol. 4, no. 1, pp. 3–66.
  18. Hanekom M., Gey van Pittius N.C., McEvoy C.C., Victor T.C., Van Helden P.D., Warren R.M. Mycobacterium tuberculosis Beijing genotype: A template for success. Tuberculosis (Edinb.), 2011, vol. 91, no. 6, pp. 510–523.
  19. Horita N., Miyazawa N., Yoshiyama T., Sato T., Yamamoto M., Tomaru K., Masuda M., Tashiro K., Sasaki M., Morita S., Kaneko T., Ishigatsubo Y. Development and validation of a tuberculosis prognostic score for smear-positive in-patients in Japan. J. Tuberc. Lung Dis., 2013, vol. 17, no. 1, pp. 54–60.
  20. Giusti G. Methods of enzymatic analysis. Ed. H. Bergmeyer, New York, 1974, vol. 2, p. 1092.
  21. Kamerbeek J., Schouls L., Kolk A., Van Agterveld M., Van Soolingen D., Kuiper S., Bunschoten A., Molhuizen H., Shaw R., Goyal M., Van Embden J. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J. Clin. Microbiol., 1997, vol. 35, no. 4, pp. 907–914.
  22. Manger I.D., Relman D.A. How the host «sees» pathogens: global gene expression resposes to infection. Curr. Opin. Immunol., 2000, vol. 12, pp. 215–218.
  23. Tang C., Holden D. Pathogen virulence genes: impliations for vaccines and drug therapy. Brit. Med. Bull., 1999, vol. 55, pp. 387–400.
  24. Thwaites G., Caws M., Chau T.T., D’Sa A., Lan N.T.N., Huyen M.N.T., Gagneux S., Anh P.T.H., Tho D.Q., Torok E., Nhu N.T.Q., Duyen N.T.H., Duy P.M., Richenberg J., Simmons C., Hien T.T., Farrar J. Relationship between Mycobacterium tuberculosis genotype and the clinical phenotype of pulmonary and meningeal tuberculosis. J. Clin. Microbiol., 2008, vol. 46, pp. 1363–1368.
  25. Tsolaki A.C., Gagneux S., Pym A.S., Goguet de la Salmoniere Y-Ol. Genomic deletions classify the Beijing/W strains as a distinct genetic lineage of Mycobacterium tuberculosis. J. Clin. Microbiol., 2005, vol. 43, pp. 3185–3191.
  26. Visser L., Blout E.R. The use of P-nitrophenyl-N-tertbutyloxylcarbonyl L-alaninate as substate for elastase. New York, 1972, p. 919.
  27. Visser M.E., Stead M.C., Walzl G., Warren R., Schomaker M., Grewal H.M.S., Swart E.C., Maartens G. Baseline predictors of sputum culture conversion in pulmonary tuberculosis: importance of cavities, smoking, time to detection and W-Beijing genotype. PLoS One, 2012, vol. 7, pp. 1–7.
  28. Salahuddin N., Tianveer M., Rao N., Akram S., Hasan Z., Hasan R. Mycobacterium tuberculosis genotypes in patients developing pulmonary tuberculosis related acute respiratory distress syndrome. Sri Lanka. J. Crit. Care, 2011, vol. 2, pp. 20–24.
  29. Sun Y.J., Ong A.K.Y., Lim T.K., Heng Ho B.C., Seah G.T., Paton N. Tuberculosis associated with Mycobacterium tuberculosis Beijing and non-Beijing genotypes: a clinical and immunological compatison. BMC Infect. Dis., 2006, vol. 6, pp. 105–110.
  30. Swith J. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin. Microbiol. Rev., 2003, vol. 16, no. 3, pp. 463–496.
  31. Wang C., Peyron P., Mestre O., Kaplan G., Van Soolingen D., Gao Q., Gicquel B., Neyrolles O. Innate immune response to Mycobacterium tuberculosis Beijing and other genotypes. PLoS One, 2010, vol. 5, pp. 13594.

Copyright (c) 2014 Titarenko O.T., Dyakova M.E., Manicheva O.A., Esmedlyaeva D.S., Dogonadze M.Z., Alexeyeva N.P., Perova T.L., Melnikova N.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies